Clinical Trial Update: Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating valsartan for prevention of acute respiratory distress syndrome in hospitalized COVID-19 patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Sars-cov-2

Drugs mentioned

• VALSARTAN (Valsartan)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Acute Respiratory Distress Syndrome, SARS-CoV-2 | Phase 4 | Status: TERMINATED